Skip to main content

CNQ: Too Bad About the Price

VALUATION MODEL FOR CNQ


The Model

We'll start by looking at CNQ's value relative to the group and then we'll look at it's dividend yield relative to its five year average. 

Group Valuation Metrics

We're looking at four valuation metrics  and then ranking them from best to worst.  The ranks are summed and a final rank is calculated.
SecurityPrice to Book
Rank
Price to Sales
Rank
PE Ratio
Rank
EV/EBITDA
Rank
SumFinal
Rank
CNQ0.0132
3
1.9171
5
17.86
3
5.92
4
152
CVE.009
4
.5659
10
na (negative)
1
23.14
2
174
HSE .0054
9
.6423
9
7.12
8
4.68
6
3210
ECA.0076
6
1.06
7
5.09
10
3.93
8
319

ALA.0089
5
.739
8
na (negative)
1
na (negative)
1
152
TOU.0052
10
2.7331
1
10.099
6
6.50
3
205
VET.0142
2
2.6826
2
12.5324
4
5.87
5
131
PXT.0196
1
2.4163
3
6.8331
9
2.45
10
236
VII.0063
8
1.2609
6
7.57
7
3.24
9
308
ARX.007     
7
2.0627 
4   
11..87 
5
4.50   
236  
CNQ doesn't look like good value relative to its peers.

Dividend Yield Relative to 5 Year Average

A rule of thumb for this metric is to only purchase a stock when it's current dividend yield is lower than its 5 year average, or in other words, less than one in the calculation forward dividend yield divided by 5 year average.

CNQ looks overvalued at the moment, not surprising, too bad I didn't get to this analysis last week.

Comments

Popular posts from this blog

11 Reasons Why INVRS is Better Than Excel Alone

If you work with your own investment models you likely use excel to build them, but excel isn’t ideal for many reasons and it costs you in other ways.   First, you need good data and it isn’t just lying around in an easy to import format.   You’re either keying it in yourself or paying money for excel downloads.   When you need data from numerous sources – price information, data from different statements and across multiple years - you must merge it from multiple sheets.   It's a n inefficient process which can lead to data corruption. After all this data is collected and merged, models built and tested, the net result is one statistic for one company.   A stand-alone number without context has limited use.   To be meaningful, you need to compare it to similar companies.       This is just a sample of the challenges.  You need software that overcomes these problems and is designed for investment model creation. Surprise!  This software exists,

NextEra - Good Dividend in the Renewable Energy Sector

NextEra had good results relative to a group of peers in a factor-based analysis. NextEra has an appealing profitability and income profile. Its price momentum looks decent, with a caveat. Its relatively small size (a small mid-cap) coupled with its industry (renewable energy) further weight the odds that this company could be a strong performer in the future. If you want in on renewable energy, we recommend NextEra. The Analysis Overview I created a portfolio of stocks in the alternative energy sector, looking specifically for companies with a market cap over $1B but less than $4B.  This is a sweet spot that offers strong potential for growth but is also substantial enough not to be too speculative. It's my believe that alternative energy is on the ascendance, where as fossil fuels will inevitably decline (NextEra isn't a pure play in this regard however, natural gas assets are part of its portfolio).  If you share this belief and you want exposure to this ma

GlaxoSmithKline Scores High in Quality

I created a portfolio of the top pharmaceutical companies trading in the US and ran a quality of earnings analysis on them.  With the highest possible score being nine, GSK scored the best with seven. Here are the results: Quality of Earnings - Major Pharmaceuticals Here's the balance of the companies in the portfolio.  We can see that AZN was the worst at two. Quality of Earnings - Major Pharmaceuticals 2 Just for laughs, lets see how GSK and AZN have performed from a price perspective. Interestingly, AZN has been outperforming GSK. It'll be interesting to say if this trend will continue or if it will, more correctly I believe, reverse.